HUP9904201A1 - Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent - Google Patents

Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent

Info

Publication number
HUP9904201A1
HUP9904201A1 HU9904201A HUP9904201A HUP9904201A1 HU P9904201 A1 HUP9904201 A1 HU P9904201A1 HU 9904201 A HU9904201 A HU 9904201A HU P9904201 A HUP9904201 A HU P9904201A HU P9904201 A1 HUP9904201 A1 HU P9904201A1
Authority
HU
Hungary
Prior art keywords
transfecting
viral
nucleic acid
gene therapy
exogenous nucleic
Prior art date
Application number
HU9904201A
Other languages
Hungarian (hu)
Inventor
Nathalie Aubailly
Patrick Benoit
Didier Branellec
Aude Le Roux
Abderrahim Mahfoudi
Nathalie Ratet
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9904201A1 publication Critical patent/HUP9904201A1/en
Publication of HUP9904201A3 publication Critical patent/HUP9904201A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Abstract

A találmány tárgya génterápiában alkalmazható transzfektálókészítmény, azzal jellemezve, hőgy egy vagy több, lipidtartalmúbűrőkkal nem rendelkező, és genőmjában legalább egy exőgénnűkleinsavat tartalmazó vírűs, és legalább egy nem virális és nemplazmid transzfektáló szer kőmbinációját tartalmazza. A találmányvőnatkőzik a készítmény segítségével előállítőtt rekőmbináns sejtre,valamint egy eljárására is nűkleinsavak sejtekbe történő átvitelére. ŕThe subject of the invention is a transfecting preparation that can be used in gene therapy, characterized by the fact that it contains a combination of one or more non-lipid-containing viruses and containing at least one exogenous nucleic acid in its genome, and at least one non-viral and non-plasmid transfecting agent. The invention is based on a recombinant cell produced with the help of the preparation, as well as a method for the transfer of nucleic acids into cells. ŕ

HU9904201A 1996-11-29 1997-11-28 Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent HUP9904201A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614693A FR2756491B1 (en) 1996-11-29 1996-11-29 TRANSFECTING COMPOSITION USEFUL IN GENE THERAPY ASSOCIATED WITH A RECOMBINANT VIRUS INCORPORATING EXOG ENE NUCLEIC ACID, A NON-VIRAL AND NON-PLASMIDIC TRANSFECTING AGENT

Publications (2)

Publication Number Publication Date
HUP9904201A1 true HUP9904201A1 (en) 2000-04-28
HUP9904201A3 HUP9904201A3 (en) 2002-01-28

Family

ID=9498192

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904201A HUP9904201A3 (en) 1996-11-29 1997-11-28 Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent

Country Status (13)

Country Link
EP (1) EP0948636A1 (en)
JP (1) JP2001514485A (en)
KR (1) KR20000057307A (en)
AU (1) AU737846B2 (en)
BR (1) BR9713434A (en)
CA (1) CA2272637A1 (en)
CZ (1) CZ188299A3 (en)
FR (1) FR2756491B1 (en)
HU (1) HUP9904201A3 (en)
IL (1) IL130053A0 (en)
NO (1) NO992577L (en)
SK (1) SK70999A3 (en)
WO (1) WO1998023765A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100764890B1 (en) * 2005-11-14 2007-10-09 한국화학연구원 Anticancer agent using liposome by polyethylenimine conjugated with DSPE and preparation method
US9273300B2 (en) * 2007-02-07 2016-03-01 Strike Bio, Inc Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
KR100980395B1 (en) 2008-06-27 2010-09-07 재단법인서울대학교산학협력재단 Polymer/DNA complex for non-viral DNA carrier
JP5944622B2 (en) * 2011-04-08 2016-07-05 株式会社ブリヂストン Gene transfer agent composition
KR102101210B1 (en) 2012-03-02 2020-04-16 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 Method for constructing functional nucleic acid molecule, and nucleic acid combination to be used in said method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646161B1 (en) * 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
FR2727679B1 (en) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
FR2730637B1 (en) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
FR2741066B1 (en) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS

Also Published As

Publication number Publication date
JP2001514485A (en) 2001-09-11
NO992577L (en) 1999-07-28
AU7401098A (en) 1998-06-22
SK70999A3 (en) 2000-03-13
CZ188299A3 (en) 1999-09-15
FR2756491A1 (en) 1998-06-05
BR9713434A (en) 2000-02-01
HUP9904201A3 (en) 2002-01-28
CA2272637A1 (en) 1998-06-04
KR20000057307A (en) 2000-09-15
IL130053A0 (en) 2000-02-29
WO1998023765A1 (en) 1998-06-04
EP0948636A1 (en) 1999-10-13
FR2756491B1 (en) 1999-01-08
AU737846B2 (en) 2001-08-30
NO992577D0 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
Hercyk et al. The vesicular stomatitis virus L protein possesses the mRNA methyltransferase activities
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
AUPN477695A0 (en) Gene therapy
ATE215990T1 (en) COMPOSITION FOR INTRODUCING NUCLEIC ACID COMPLEXES INTO HIGHER EUKARYOTIC CELLS
NO962791L (en) Preparations containing nucleic acids, their preparation and use
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
FI875082A0 (en) DNA SEQUENCE DERIVERADE FRAON GENOM AV PAPILLOMAVIRUS, DERAS ANVAENDNING FOER IN VITRO DIAGNOSTISKA AENDAMAOL; SAMT FRAMSTAELLNING AV ANTIGENISKA KOMPOSITIONER.
UA42089C2 (en) Influenza vaccine based on envelope antigenic proteins of influenza virus, method for its production
EE05138B1 (en) Recombinant MVA Virus and Its Uses, Isolated Eukaryotic Cell, Method for Recombinant HIV Nef Protein, and Vaccine
DE59913833D1 (en) STRUCTURAL PROTEIN OF AAV, ITS MANUFACTURE AND USE
WO1999020766A3 (en) NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
DK0462187T3 (en) Pharmaceutical composition which can be used for the prevention or treatment of papilloma virus-induced tumors
WO2000077233A3 (en) Complement-resistant non-mammalian dna viruses and uses thereof
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
HUP9902710A2 (en) Recombinant swinepox virus
NO983946L (en) Parapox viruses containing foreign DNA, preparation and use thereof in vaccines
HUP9904201A1 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
DK0843731T3 (en) Gene therapy adenovirus vectors
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
AU7514087A (en) Vaccine containing the protein f of the aids virus
WO1998024912A3 (en) Recombinant plague vaccine
WO1999057284A3 (en) Attenuated influenza viruses
BR0016672A (en) Nucleic acid vaccine construct, vaccine composition, use of a nucleic acid vaccine construct, and method of vaccination of a mammal against tumors
NZ511168A (en) Recombinant CELO virus and CELO virus DNA